Eli Lilly and Company $LLY Position Raised by Northside Capital Management LLC

Key Points

• Northside Capital Management LLC raised its holdings in Eli Lilly by 13.6%, increasing its position to 20,053 shares valued at approximately $15.6 million.
• Insider buying activity includes Director J Erik Fyrwald purchasing 1,565 shares at $642.33 each, reflecting confidence in the company's future.
• Eli Lilly's most recent earnings report revealed an EPS of $6.31, exceeding analyst expectations, with a quarterly revenue increase of 37.6% year-over-year.

Northside Capital Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 13.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,053 shares of the company's stock after acquiring an additional 2,400 shares during the period. Eli Lilly and Company makes up 1.2% of Northside Capital Management LLC's holdings, making the stock its 22nd largest position. Northside Capital Management LLC's holdings in Eli Lilly and Company were worth $15,632,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. raised its stake in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. GAMMA Investing LLC raised its stake in Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP raised its stake in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Eli Lilly and Company by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock valued at $4,808,443,000 after acquiring an additional 682,203 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $747.29 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $707.27 billion, a price-to-earnings ratio of 48.84, a PEG ratio of 1.05 and a beta of 0.47. The stock's fifty day simple moving average is $736.98 and its 200 day simple moving average is $768.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Guggenheim cut their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their price objective for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. JPMorgan Chase & Co. dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.